{"id":"W4283780125","doi":"10.1016/j.annonc.2022.04.412","title":"SO-13 Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Sorafenib; Medicine; Pembrolizumab; Oxaliplatin; Internal medicine; Hepatocellular carcinoma; Adverse effect; Oncology; Placebo; Open label; Cancer; Immunotherapy; Pathology; Alternative medicine; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001913197,0.0007193122,0.001862108,0.0003574648,0.0002262095,0.001082937,0.0003873954,0.000499081,0.001314134],"category_scores_gemma":[0.001538535,0.0003666035,0.00194914,0.0006658669,0.0003468111,0.001052691,0.0003475638,0.001664203,0.0002988714],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006597778,"about_ca_system_score_gemma":0.0007043533,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009996145,"about_ca_topic_score_gemma":0.003981654,"domain_scores_codex":[0.9994699,0.0002379485,0.00004350154,0.0000720569,0.00009162278,0.00008495722],"domain_scores_gemma":[0.9990659,0.0002736796,0.0003412237,0.00007044701,0.00008582541,0.0001628741],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4620822,0.004614619,0.1003404,0.0045668,0.0197018,0.0003558668,0.0003028798,0.006837521,0.01389634,0.0006084631,0.01513494,0.3715581],"study_design_scores_gemma":[0.3584896,0.1019652,0.4672022,0.001029202,0.02471007,0.001389176,0.0003817262,0.006602561,0.004769443,0.002048607,0.03118719,0.0002250613],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9637834,0.02668862,0.0006698817,0.0009454399,0.0002465114,0.0003754733,0.003857731,0.00007734606,0.00335556],"genre_scores_gemma":[0.9807375,0.009405718,0.0007409782,0.0007931141,0.0001844515,0.0003006453,0.006652209,0.00002107496,0.001164206],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001913197,"threshold_uncertainty_score":0.01011813,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1766228967951924,"score_gpt":0.3642284476012224,"score_spread":0.18760555080603,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}